Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Assets (2019 - 2025)

Legend Biotech filings provide 7 years of Current Assets readings, the most recent being $1.2 billion for Q4 2025.

  • On a quarterly basis, Current Assets fell 2.87% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 2.87% decrease, with the full-year FY2025 number at $1.2 billion, down 2.87% from a year prior.
  • Current Assets hit $1.2 billion in Q4 2025 for Legend Biotech, roughly flat from $1.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.6 billion in Q2 2023 to a low of $475074.0 in Q1 2021.
  • Median Current Assets over the past 5 years was $1.2 billion (2025), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Current Assets: skyrocketed 181849.97% in 2022 and later decreased 14.28% in 2024.
  • Legend Biotech's Current Assets stood at $949.8 million in 2021, then rose by 15.72% to $1.1 billion in 2022, then soared by 36.27% to $1.5 billion in 2023, then decreased by 14.28% to $1.3 billion in 2024, then fell by 2.87% to $1.2 billion in 2025.
  • The last three reported values for Current Assets were $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.